Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

RPRX Royalty Pharma plc Class A Ordinary Shares
$47.54 2.73% +1.26
Notify me if price changes either direction
Interactive Brokers Logotype

Buy RPRX stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 27.5B
Enterprise value 31.4B
Trailing PE 25.960674
Forward PE 8.482899
PEG Ratio 8.482899
Enterprise to EBITDA 20.064
Enterprise to revenue 13.19
Price to book MRQ 3.0584419
Price to sales TTM 11.238908

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2025-12-31
Revenue (TTM) 2.4B
EBITDA 1.6B
Diluted EPS TTM 1.78
Total Cash (MRQ) 637.5M
Current ratio (MRQ) 2.402
Operating Cash Flow (TTM) 2.5B

RPRX trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent RPRX News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.